RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer
While the ASCO Meeting Abstract from the 2022 ASCO Annual Meeting has cited that the average cost for the first year of HR+/HER2 negative was US$192,367 per patient, it also referenced that the 2nd year of treament cost for HR+/HER2 negative breast cancer would be approximately US$169,0000 per patient for those who benefited from treatment and continued on with their lives. The third year of treatment cost would be approximately $US166,000 per patient.
So after the first year ONCY or its Big Pharma acquirer would be having annual sales of pelareorep hovering in the vicinity US$10.5 Billion for first time / year 1 patients PLUS generous sales revenue generated from patients moving into their 2nd year of pelareorep treatment PLUS further sales generated from pelareorep in the 3rd year of pelareorep patient treatment and so on.
Thus the cumulative revenue stream for pelareorep in HR+/HER2- breast cancer would be the annual gross sales total of Year 1 sales revenue + diminished continuing sales revenue from Year 2 + further diminishing continuing sales revenue from Year 3 sueviving patients .... and so on ... all the while 55,000 new patients keep entering into Year 1 of treatment
What ONCY or its Big Pharma acquirer will therefore be able to build is a significant and lucrative revenue stream on the sales of pelareorep in this indication alone.